In a significant development for the phenylketonuria community, the U.S. Food and Drug Administration (FDA) has approved an expanded indication for Palynziq to include adolescents aged 12 years and older with uncontrolled PKU. This decision marks a new chapter in the management of this rare genetic condition and offers hope to families navigating the complex dietary and medical challenges of adolescence.
According to an announcement from BioMarin Pharmaceutical Inc., the U.S. Food and Drug Administration has approved a supplemental Biologics License Application for Palynziq, also known as pegvaliase-pqpz, extending its use to pediatric patients 12 years of age and older who have blood phenylalanine levels greater than 600 micromol per liter despite existing management.
This blog explores what the approval means, how Palynziq works, key clinical data from the PEGASUS trial, safety considerations, and what families should know moving forward.
Phenylketonuria, commonly known as PKU, is a rare inherited metabolic disorder caused by deficiency of the phenylalanine hydroxylase enzyme. Without this enzyme, the amino acid phenylalanine accumulates in the blood and becomes toxic to the brain.
Globally, PKU affects an estimated 70,000 people in regions where BioMarin operates. In countries with newborn screening programs, most cases are diagnosed shortly after birth. Early detection has dramatically improved outcomes. However, lifelong management remains demanding.
Adolescence introduces new obstacles for individuals with PKU:
Traditional management relies on a severely phenylalanine-restricted diet supplemented with specialized medical foods. Maintaining strict adherence during teenage years can be extremely challenging. Poor blood phenylalanine control in adolescence is associated with neurocognitive impairment, mood disturbances, and executive function deficits.
The expanded approval of Palynziq addresses a critical gap in care during this vulnerable life stage.
Palynziq is an enzyme substitution therapy designed to reduce blood phenylalanine concentrations in individuals with PKU. Unlike therapies that depend on a patient’s specific genetic mutation, Palynziq works independently of genotype.
It contains a PEGylated version of phenylalanine ammonia lyase, an enzyme that breaks down phenylalanine into substances the body can safely eliminate. By-substituting the deficient enzyme activity, it helps reduce circulating phenylalanine levels.
Before this expanded indication, Palynziq was approved only for adults with uncontrolled PKU. The new decision now makes it available to eligible adolescents as young as 12.
The FDA’s decision was based on data from PEGASUS, a Phase 3 multicenter open label randomized controlled study. The trial evaluated safety and efficacy of Palynziq compared to diet alone in adolescents aged 12 to under 18 years with blood phenylalanine levels above 600 micromol per liter.
Participants receiving Palynziq demonstrated statistically significant reductions in blood phenylalanine compared with those managed with diet alone.
Nearly half of participants reached levels below guideline recommendations by the end of Part 1 of the study. Among those who responded strongly, some achieved phenylalanine levels below 120 micromol per liter, with dramatic reductions from baseline.
Interestingly, some participants with very low phenylalanine levels were able to significantly increase intact protein intake while reducing or discontinuing medical foods. This suggests potential flexibility in dietary management for responders, although this must always be guided by healthcare professionals.
While the efficacy data are promising, Palynziq carries significant safety considerations that families must understand.
Palynziq includes a boxed warning for anaphylaxis. Severe allergic reactions have been reported and may occur at any time during treatment.
Because of this risk:
In adolescent trials, approximately 11 percent of treated patients experienced an anaphylaxis episode. This rate is similar to what has been observed in adult populations.
The most frequently reported side effects in adolescents included:
Many adverse reactions occur during the induction and titration phases and tend to decrease in frequency during maintenance therapy.
Injection site infections, including serious cases requiring hospitalization, have also been reported. Proper training in aseptic injection technique and site rotation is essential.
Blood phenylalanine levels must be closely monitored during treatment.
Recommendations include:
Very low phenylalanine levels, known as hypophenylalaninemia, may require dosage adjustment or dietary modification.
The expanded approval provides a new treatment option at a critical developmental stage.
For many teenagers, maintaining a rigid PKU diet can feel socially isolating. The possibility of better phenylalanine control and greater dietary flexibility may improve quality of life for selected patients.
However, this therapy is not appropriate for everyone. It requires:
Shared decision-making between families, metabolic specialists, and patients is crucial.
BioMarin has indicated it is also pursuing approval from the European Medicines Agency to extend adolescent access within the European Union. Regulatory review is ongoing.
Palynziq is currently approved in more than 35 countries worldwide for adult PKU, and now in the United States for eligible adolescents aged 12 and older.
Over the past two decades, treatment options for PKU have expanded beyond dietary restriction alone. The approval of Palynziq for adolescents reflects continued progress in rare disease therapeutics.
Key themes shaping the future of PKU care include:
For families managing PKU, this approval represents another tool in a growing therapeutic toolkit.
Adolescents aged 12 years and older with PKU who have uncontrolled blood phenylalanine concentrations above 600 micromol per liter despite existing management may be eligible.
Dietary monitoring remains important. Some patients may achieve greater dietary flexibility, but any changes should be supervised by healthcare providers.
The most serious risk is anaphylaxis. Patients must carry epinephrine and participate in the REMS program.
Palynziq is administered by subcutaneous injection using a carefully structured induction, titration, and maintenance dosing regimen.
Press release from BioMarin Pharmaceutical Inc. announcing FDA approval of supplemental Biologics License Application for Palynziq in adolescents aged 12 years and older with PKU, February 27, 2026.
This article is for informational and educational purposes only and is optimized for search visibility regarding FDA approval of Palynziq for adolescents with PKU. It is not intended as medical advice, diagnosis, or treatment guidance. Patients and caregivers should consult a qualified healthcare professional before starting, stopping, or modifying any treatment. Treatment decisions should always be based on individualized medical assessment and professional guidance.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.